BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein ...

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

Only last month, the Massachusetts-based company was outlining plans to lay off half of its employees in order to focus its ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

| AI solutions in clinical trials are only as good as the data they process. With a focus on quality, AI can be harnessed to ...

Aiming T-cell engagers at autoimmune diseases continues to be a red-hot deal-making target, as evidenced by Otsuka ...

The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with ...

A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in ...

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity ...

Johnson & Johnson is launching what it describes as the first and only daily disposable, multifocal and toric contact lens for people who have both astigmatism and presbyopia, where n | J&J said ...